Detalles de la búsqueda
1.
Clinico-pathologic relationships with Ki67 and its change with short-term aromatase inhibitor treatment in primary ER + breast cancer: further results from the POETIC trial (CRUK/07/015).
Breast Cancer Res
; 25(1): 39, 2023 04 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-37046348
2.
Relationship between ER expression by IHC or mRNA with Ki67 response to aromatase inhibition: a POETIC study.
Breast Cancer Res
; 24(1): 61, 2022 09 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-36096872
3.
Correction to: Combination of mTORC1/2 inhibitor vistusertib plus fulvestrant in vitro and in vivo targets oestrogen receptor-positive endocrine-resistant breast cancer.
Breast Cancer Res
; 22(1): 14, 2020 Jan 31.
Artículo
en Inglés
| MEDLINE | ID: mdl-32005287
4.
Combination of mTORC1/2 inhibitor vistusertib plus fulvestrant in vitro and in vivo targets oestrogen receptor-positive endocrine-resistant breast cancer.
Breast Cancer Res
; 21(1): 135, 2019 12 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-31801615
5.
Heterogeneity in global gene expression profiles between biopsy specimens taken peri-surgically from primary ER-positive breast carcinomas.
Breast Cancer Res
; 18(1): 39, 2016 Apr 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-27036195
6.
ER and HER2 expression are positively correlated in HER2 non-overexpressing breast cancer.
Breast Cancer Res
; 14(2): R46, 2012 Mar 14.
Artículo
en Inglés
| MEDLINE | ID: mdl-22417870
7.
HER2-enriched subtype and novel molecular subgroups drive aromatase inhibitor resistance and an increased risk of relapse in early ER+/HER2+ breast cancer.
EBioMedicine
; 83: 104205, 2022 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-35985932
8.
Triplet Therapy with Palbociclib, Taselisib, and Fulvestrant in PIK3CA-Mutant Breast Cancer and Doublet Palbociclib and Taselisib in Pathway-Mutant Solid Cancers.
Cancer Discov
; 11(1): 92-107, 2021 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-32958578
9.
Extreme loss of immunoreactive p-Akt and p-Erk1/2 during routine fixation of primary breast cancer.
Breast Cancer Res
; 12(5): R76, 2010.
Artículo
en Inglés
| MEDLINE | ID: mdl-20920193
10.
Pre-surgical study of the biological effects of the selective cyclo-oxygenase-2 inhibitor celecoxib in patients with primary breast cancer.
Breast Cancer Res Treat
; 123(3): 829-36, 2010 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-20697803
11.
Abiraterone in patients with recurrent epithelial ovarian cancer: principal results of the phase II Cancer of the Ovary Abiraterone (CORAL) trial (CRUK - A16037).
Ther Adv Med Oncol
; 12: 1758835920975352, 2020.
Artículo
en Inglés
| MEDLINE | ID: mdl-33854564
12.
Association of p27 and Cyclin D1 Expression and Benefit from Adjuvant Trastuzumab Treatment in HER2-Positive Early Breast Cancer: A TransHERA Study.
Clin Cancer Res
; 24(13): 3079-3086, 2018 07 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-29530933
13.
Proliferation and apoptosis as markers of benefit in neoadjuvant endocrine therapy of breast cancer.
Clin Cancer Res
; 12(3 Pt 2): 1024s-1030s, 2006 Feb 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-16467120
14.
Discovery of naturally occurring ESR1 mutations in breast cancer cell lines modelling endocrine resistance.
Nat Commun
; 8(1): 1865, 2017 11 30.
Artículo
en Inglés
| MEDLINE | ID: mdl-29192207
15.
Biomarker changes during neoadjuvant anastrozole, tamoxifen, or the combination: influence of hormonal status and HER-2 in breast cancer--a study from the IMPACT trialists.
J Clin Oncol
; 23(11): 2477-92, 2005 Apr 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-15767642
16.
Short-term changes in Ki-67 during neoadjuvant treatment of primary breast cancer with anastrozole or tamoxifen alone or combined correlate with recurrence-free survival.
Clin Cancer Res
; 11(2 Pt 2): 951s-8s, 2005 Jan 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-15701892
17.
Breast cancer risk variants at 6q25 display different phenotype associations and regulate ESR1, RMND1 and CCDC170.
Nat Genet
; 48(4): 374-86, 2016 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-26928228
18.
Comparison of the systemic and intratumoral effects of tamoxifen and the aromatase inhibitor vorozole in postmenopausal patients with primary breast cancer.
J Clin Oncol
; 20(4): 1026-35, 2002 Feb 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-11844826
19.
Correlation between cyclooxygenase-2 expression and angiogenesis in human breast cancer.
Clin Cancer Res
; 9(7): 2651-6, 2003 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-12855643
20.
Antiproliferative Effect of Lapatinib in HER2-Positive and HER2-Negative/HER3-High Breast Cancer: Results of the Presurgical Randomized MAPLE Trial (CRUK E/06/039).
Clin Cancer Res
; 21(13): 2932-40, 2015 Jul 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-25398453